Wells Fargo & Company Annovis Bio, Inc. Transaction History

Wells Fargo & Company

$407 Billion
Q2 2024

A detailed history of Wells Fargo & Company transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 8,747 shares of ANVS stock, worth $76,361. This represents 0.0% of its overall portfolio holdings.

Number of Shares

8,747

Previous 8,801 0.61%

Holding current value

$76,361

Previous $104,000 51.92%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$4.82 - $18.01 $260 - $972	-54 Reduced 0.61%	8,747 $50,000
Q1 2024 May 10, 2024	BUY	$8.47 - $18.93 $8 - $18	1 Added 0.01%	8,801 $104,000
Q4 2023 Feb 09, 2024	BUY	$5.55 - $19.62 $49 - $176	9 Added 0.1%	8,800 $164,000
Q3 2023 Nov 13, 2023	BUY	$9.37 - $14.12 $9 - $14	1 Added 0.01%	8,791 $83,000
Q2 2023 Aug 15, 2023	BUY	$11.95 - $16.31 $71 - $97	6 Added 0.07%	8,790 $125,000
Q1 2023 May 12, 2023	BUY	$12.33 - $22.1 $12 - $22	1 Added 0.01%	8,784 $135,000
Q4 2022 Feb 13, 2023	BUY	$10.99 - $13.8 $10 - $13	1 Added 0.01%	8,783 $117,000
Q3 2022 Nov 14, 2022	BUY	$10.26 - $21.81 $10 - $21	1 Added 0.01%	8,782 $121,000
Q2 2022 Aug 12, 2022	BUY	$8.61 - $13.87 $34 - $55	4 Added 0.05%	8,781 $99,000
Q4 2021 Feb 14, 2022	SELL	$17.58 - $37.67 $17,580 - $37,670	-1,000 Reduced 10.23%	8,777 $155,000
Q3 2021 Nov 15, 2021	BUY	$30.95 - $120.97 $285,978 - $1.12 Million	9,240 Added 1720.67%	9,777 $310,000
Q2 2021 Aug 16, 2021	BUY	$21.55 - $96.1 $11,033 - $49,203	512 Added 2048.0%	537 $47,000
Q1 2021 May 13, 2021	BUY	$8.15 - $38.44 $16 - $76	2 Added 8.7%	25 $1,000
Q3 2020 Nov 05, 2020	BUY	$3.84 - $6.78 $88 - $155	23 New	23 $0

Others Institutions Holding ANVS

# of Institutions

Shares Held

946K

Call Options Held

642K

Put Options Held

1.57M

View Full List

About Annovis Bio, Inc.

Ticker ANVS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,163,920
Market Cap $71.3M
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...

More about ANVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Annovis Bio, Inc. Transaction History